Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
In a recent transaction involving Corcept Therapeutics Inc (NASDAQ:CORT), a $7.49 billion market cap company that has delivered an impressive 125.9% return over the past year, Director Daniel Swisher executed a notable stock sale. On June 10, 2025, Swisher sold 2,200 shares of common stock at a price of $70.61 per share, amounting to a total of $155,342. This transaction was conducted under a 10b5-1 trading plan, which had been previously established on August 1, 2024.
Additionally, Swisher exercised stock options to acquire 2,200 shares at a conversion price of $14.08 per share, totaling $30,976. The shares acquired through this option exercise were subsequently sold on the same day.
Moreover, Swisher was granted stock options for 15,000 shares with an exercise price of $72.27, which will vest monthly over the next year, contingent on his continued service. Following these transactions, Swisher holds no shares of common stock directly.
These activities reflect Swisher’s ongoing engagement with Corcept Therapeutics, as he navigates his stock holdings and options within the company.
In other recent news, Corcept Therapeutics announced promising results from its Phase 3 ROSELLA trial, which evaluated the efficacy of relacorilant combined with nab-paclitaxel for treating platinum-resistant ovarian cancer. The trial met its primary endpoint by showing a 30% reduction in the risk of disease progression for patients on the combination therapy, with a median progression-free survival of 6.5 months compared to 5.5 months for those on monotherapy. Additionally, an interim analysis revealed a significant extension in overall survival, with patients in the combination group reaching a median of 16.0 months versus 11.5 months for the control group. Analysts from H.C. Wainwright maintained their Buy rating and a $145 price target, emphasizing the potential impact of these findings on Corcept’s stock valuation. Meanwhile, Piper Sandler reiterated an Overweight rating with a $131 price target, noting the company’s strong performance in the hypercortisolism market and potential growth from relacorilant. Corcept’s first-quarter earnings per share exceeded expectations at $0.17, although revenue fell short at $157.2 million against the anticipated $177.9 million. Despite the revenue miss, Corcept’s management remains optimistic, projecting 2025 sales between $900 million and $950 million. The company is working on regulatory applications in the U.S. and Europe to expedite relacorilant’s availability, aiming to establish it as a new standard of care for ovarian cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.